Therapeutic approaches to cerebral vasospasm complicating ruptured aneurysm

Neurology International

Volumn 1, Issue 1, 2009, Pages 46-51

  Barbarawi, Mohamed ^a   Smith, Sarah F ^b   Jamous, Mohamed Abu ^a   Haboub, Hazem ^a   Suhair, Qudsieh ^c   Abdullah, Shboul ^a  

^a KING ABDULLAH UNIVERSITY HOSPITAL   (Jordan)

^b ROYAL NORTH SHORE HOSPITAL   (Australia)

^c HASHEMITE UNIVERSITY   (Jordan)

Author keywords

Cerebral vasospam; Ruptured aneurysm

Indexed keywords

EID: 84867038045     PISSN: 20358385     EISSN: 20358377     Source Type: Journal    
DOI: 10.4081/ni.2009.e13     Document Type: Article

References (60)

1. Oertel M, Boscardin WJ, Obrist WD, et al. Post traumatic vasospasm: The epidermiology, severity, and time course of underestimated phenomenon: A prospective study performed in 299 patients. J Neurosurg 2005;103:812-24.
2. Findlay JM, Macdonald RL, Weir BKA. Current concepts of pathophysiology and management of cerebral vasospasm following aneurysmal subarachnoid hemorrhage. Cerebrovasc Brain Metab Rev 1991;3:336-61.
3. Oshiro EM, Walter KA, Piantadosi S, et al. A new subarachnoid grading system based on the Glasgow Coma Scale: A comparison with Hunt and Hess World Federation of Neurosurgical Surgeons Scales in a clinical series. Neurosurgery 1997;41:140-7.
4. Fisher CM, Kistler JP, Davis JM. Relation of cerebral vasospasm to subarachnoid haemorrhage visualized by computed tomographic scanning. Neurosurgery 1980;6:1-9.
5. Macdonald RL, Rosengart A, Huo D, Karrison T. Factors associated with the development of vasospasm after planned surgical treatment of aneurysmal subarachnoid hemorrhage. J Neurosurg 2003;99:644-52.
6. Weir BKA, Macdonald RL, Stoodly M. Etiology of cerebral vasospasm. Acta Neurochir Suppl.1999;72:27-46.
7. Weir BKA. The incidence and onset of a vasospasm after subarachnoid hemorrhage from ruptured aneurysm, in Wilkins RH (Ed): Cerebral Arterial Vasospasm. Baltimore, Williams & Wilkins 1980;302-5.
8. Dorsch NW. Therapeutic approaches to vasospasm in subarachnoid hemorrhage. Curr Opin Crit Care 2002;8:128-33.
9. Wikins RH. Attempts at prevention or treatment of intracranial arterial spasm: An update. Neurosurgery 1986;18:808-25.
10. Komotar RJ, Zacharia BE, Valhora R, et al. Advances in vasospasm treatment and prevention. J Neurol Sci. 2007;261:134-42
11. Kassell NF, Sasaki T, Colohan ART, Nazar G. Cerebral vasospasm following aneurismal subarachnoid haemorrhage. Stroke 1985;16:562-72.
12. Harrod CG, Bendok Bernard RB. Prediction of cerebral vasospasm in patients presenting with aneurysmal subarachnoid hemorrhage: A review. Neurosurgery 2005;56:633-54.
13. Dietrich HH, Dacey RG. Molecular keys to the problems of cerebral vasospasm. Neurosurgery 2000;46:517-30.
14. Macdonald RL, Weir BKA. A review of hemoglobin and pathogenesis of cerebral vasospasm. Stroke 1991;22:971-82.
15. Smith RR, Clower BR, Grotendorst GM, et al. Arterial wall changes in early human vasospasm. Neurosurgery 1985;16:171-6.
16. Melon E. Pathophysiology and principles of treatment of vasospasm. J Neuroradiol 1999;26:30-5.
17. Paschen W. Role of calcium in neuronal cell injury: Which subcellular compartment is involved? Brain Res Bull 2000;53:409-13.
18. Lefranc F. Cerebral vasospasm: Molecular analysis. Bull Mem Acad R Med Belg 2003; 158:258-64.
19. Woszczyk A, Deinsberger W, Boker DK. Nitric oxide metabolites in cisternal CSF correlate with cerebral vasospasm in patients with a subarachnoid haemorrhage. Acta Neurochir (Wien) 2003;145:257-63.
20. Juvela S. Plasma endothelin concentrations after subarachnoid hemorrge. J Neurosurg 2000;92:390-400.
21. Vajkoczy P, Meyer B, Weidauer S, et al. Clazosentan (AXV-034343), a selective endothelin A receptor antagonist, in the prevention of cerebral vasospasm following severe aneurismal subarachnoid hemorrhage: Results of a randomized, doubleblind, placebo-controlled, multicenter phase IIa study. J Neurosurg 2005;103: 9-17.
22. Chow M, Dumont AS, Kassell NF. Endothelin receptor antagonists and cerebral vasospasm: An update. Neurosurgery 2002; 51:1333-42.
23. Yamaguchi-Okada M, Nishizawa S, Koide M, Nonaka Y. Biomechanical and phenotypic changes in the vasospastic canine basilar artery after subarachnoid hemorrhage. J Appl Physiol 2005;99:2045-52.
24. Janjua N, Mayer SA. Cerebral vasospasm after subarachnoid hemorrhage. Curr Opin Crit Care 2003;9:113-9.
25. Schuknecht B. Endovascular treatment of cerebral vasospasm following aneurismal subarachnoid hemorrhage. Acta Neurochir Suppl 2005;94:47-51.
26. Shatalov VI, Shchegolev AV. Effect of infusion therapy on central hemodynamics and the outcome of treatment in patients with subarachnoidal hemorrhages. Anesteziol Reanimatol 2005;4:55-8.
27. Seiler RW, Grolimund P, Aaslid R, Huber P, Nornes H. Cerebral vasospasm evaluated by transcranial ultrasound correlated with clinical grades and CT visualized subarachnoid haemorrhge. J Neurosurgery 1995;82:55-62. [FullText]
28. Lindegaard KF. Nornes H, Bakke SJ, et al. Cerebral vasospasm diagnosis by means of angiographic and blood velocity measurements. Acta Neurochir (Wien) 1989;100:12-24.
29. Gupta D, Sharma BS, Gupta SK, et al. Postoperative hypertensive-hypervolaemic -haemodilution (Triple H) therapy in the treatment of vasospasm following aneurysmal subarachnoid haemorrhage. Neurol India 2000;48:126-31.
30. Kassell NF, Peerless SJ, Durward QJ et al. Treatment of ischemic deficits from vasospasm with intravascular volume expansion and induced arterial hypertension. Neurosurgery 1982;11:337-43.
31. Treggiari MM, Walder B, Suter PM, Romand JA. Systematic review of the prevention of delayed ischemic neurological deficits with hypertension, hypervolemia, and hemodilution therapy following subarachnoid hemorrhage. J Neurosurg 2003;98:978-84.
32. Rabinstein AA, Wijdicks EF. Cerebral Vasospasm in Subarachnoid Hemorrhage. Curr Treat Options Neurol 2005;7:99-107.
33. Stullken EH Jr, Johnston WE, Prough DS, et al. Implications of nimodipine prophylaxis of cerebral vasospasm on anesthetic management during intracranial aneurysm clipping. J Neurosurg 1985; 62:200-5.
34. Wu CT, Wong CS, Yeh CC, et al. Treatment of cerebral vasospasm after subarachnoid hemorrhage-a review. Acta Anaesthesiol Taiwan 2004;42:215-22.
35. Biondi A, Ricciardi GK, Puybasset L, Borel CO. Intra-arterial nimodipine for the treatment of symptomatic cerebral vasospasm after aneurysmal subarachnoid hemorrhage: Preliminary results. AJNR Am J Neuroradiol 2004; 25:1067-76.
36. Hui C, Lau KP. Efficacy of intra-arterial nimodipine in the treatment of cerebral vasospasm complicating subarachnoid haemorrhage. Clin Radiol 2005;60:1030-6.
37. Han RQ, Wang BG, Li SR, et al. The effect of intraoperative continuous nimodipine infusion on cerebral vasospasm during intracranial aneurysm surgery. Chinese J Surg 2004;42:1489-92.
38. Muir KW, Lees KR. A randomized, doubleblind, placebo-controlled pilot trial of intravenous magnesium sulfate in acute stroke. Stroke 1995;26:1183-8. 39. Collignon FP, Friedman JA, Piepgras DG, et al. Serum magnesium levels as related to symptomatic vasospasm and outcome following aneurysmal subarachnoid hemorrhage. Neurocritical Care 2004;1:441-8.
39. Macdonald RL, Curry DJ, Aihara Y, et al. Magnesium and experimental vasospasm. J Neurosurgery 2004;100:106-11.
40. Veyna RS, Seyfried D, Burke DG, et al. Magnesium sulfate therapy after aneurismal subarachnoid hemorrhage. J Neurosurgery 2002;96:510-4.
41. Keith WM, Kennedy RL. Dose optimization of intravenous magnesium sulfate after acute stroke. Stroke 1998;29: 918-23.
42. Yahia AM, Kirmani JF, Qureshi AI, et al. The safety and feasibility of continuous intravenous magnesium sulfate for prevention of cerebral vasospasm in aneurismal subarachnoid hemorrhage. Neurocrit Care 2005;3:16-23.
43. van den Bergh WM, Algra A, Van KF, et al. Magnesium sulfate in aneurysmal subarachnoid hemorrhage: A randomized controlled trial. Stroke 2005;36:1011-5.
44. Chia RY, Hughes RS, Morgan MK. Magnesium: A useful adjunct in the prevention of cerebral vasospasm following aneurysmal subarachnoid haemorrhage. J Clin Neurosci 2002;9: 279-81.
45. Hoh BL, Ogilvy CS. Endovascular treatment of cerebral vasospasm: Transluminal balloon angioplasty, intra-arterial papaverine, and intra-arterial nicardipine. Neurosurg Clin N Am 2005;16:501-16.
46. Clouston JE, Numaguchi Y, Zoarski GH, et al. Intra-arterial papaverine infusion for cerebral vasospasm after subarachnoid hemorrhage. AJNR Am J Neuroradiol 1995;16:27-38.
47. Kaku Y, Yonekawa Y, Tsukahara T, Kazekawa K. Superselective intra-arterial infusion of papaverine for the treatment of cerebral vasospasm after subarachnoid hemorrhage. J Neurosurg 1992;77:842-7.
48. Smith WS, Dowd CF, Johnston SC, et al. Neurotoxicity of intra-arterial papaverine preserved with chlorobutanol used for the treatment of cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Stroke 2004;35:2518-22.
49. Liu JK, Tenner MS, Gottfried ON, et al. Efficacy of multiple intra-arterial papaverine infusions for improvement in cerebral circulation time in patients with recurrent cerebral vasospasm. J Neurosurg 2004; 100:414-21.
50. Badjatia N, Topcuoglu MA, Pryor JC, Rabinov JD. Preliminary experience with intra-arterial nicardipine as a treatment for cerebral vasospasm. AJNR Am J Neuroradiol 2004; 25:819-26.
51. Murai Y, Kominami S, Kobayashi S, et al. The long term effects of transluminal balloon angioplasty for vasospasm after subarachnoid hemorrhage: Analysis of cerebral blood flow and reactivity. Surg Neurol 2005;64:122-6.
52. Zubkov Y, Nikiforov BM, Shustin VA. Balloon catheter technique for dilatation of constricted cerebral arteries after aneurysmal subarachnoid hemorrhage. Acta Neurochir 1984;70:65-79.
53. Morgan MK, Jonker B, Finfer S, et al. Aggressive management of aneurismal subarachnoid haemorrhage based on a papaverine angioplasty protocol. J Clin Neurosci 2000;7:305-8.
54. Rabinstein AA, Friedman JA, Nichols DA, et al. Predictors of outcome after endovascular treatment of cerebral vasospasm. AJNR Am J Neuroradiol 2004;25:1778-82.
55. Selman WR, Spetzler RF. Therapeutics for focal cerebral ischemia. Neurosurgery 1980;6:446-52.
56. Altura BM, Altura BT. Pharmacologic inhibition of cerebral vasospasm in ischemia, hallucinogen ingestion, and hypomagnesemia: Barbiturates, calcium antagonists, and magnesium. Am J Emerg Med 1983;1:180-90.
57. Kassell NF, Peerless SJ, Drake CG, et al. Treatment of ischemic deficits from cerebral vasospasm with high dose barbiturate therapy. Neurosurgery 1980;7:593-7.
58. Miyagi K, Ishijima B, Sato F, et al. Indication for, the method of, and result of the prophylactic use of barbiturate therapy (B-therapy) against cerebral infarct from cerebral arterial vasospasm due to ruptured aneurysm. No Shinkei Geka 1984; 12:303-10.
59. Cordato DJ, Herkes GK, Mather LE, et al. Barbiturates for acute neurological and neurosurgical emergencies – do they still have a role? J Clin Neurosci 2003;10:283-8.
60. Lin CL, Dumont AS, Calisaneller T, et al. Monoclonal antibody against E selectin attenuates subarachnoid hemorrhageinduced cerebral vasospasm. Surg Neurol 2005;64:201-5.